Brazil · Delayed Price · Currency is BRL Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw strong sales growth of 14.3%, robust digital expansion, and a 32.6% rise in private label sales. EBITDA and cash flow improved, while net income was impacted by higher interest rates. The outlook remains positive, with continued focus on digital, private label, and generics.
-
Q2 2025 saw nearly 20% sales growth, strong EBITDA and net income gains, and continued market share expansion, driven by digital, private label, and store expansion strategies. Positive trends are expected to continue, with further margin improvements and growth in key categories.
-
Q1 2025 saw 15.9% sales growth, stable 29.4% retail gross margin, and 7% EBITDA growth, driven by mature store productivity, digital expansion, and private label gains. Market share increased for the 20th consecutive quarter, with strong cash flow and low leverage.